Cleo Diagnostics (ASX:COV) posted a 48% jump in annual loss to $5.9 million amid key progress in its ovarian cancer diagnostic test, including completion of a pivotal US trial and preparations for FDA 510(k) submission.
- Loss after tax increased 48.4% to $5.9 million
- Revenues declined 31.6% to $232,000
- Pivotal US clinical trial completed with 800+ participants
- FDA pre-submission feedback positive; Analytical Validation underway
- Plans US commercial launch via existing CPT code post-clearance
Financials Reflect Heavy R&D Investment
Cleo Diagnostics Limited (ASX:COV) has reported a widening net loss of $5.94 million for the year ended 30 June 2026, up 48.4% from $4.0 million the previous year. Revenue from ordinary activities fell 31.6% to a modest $232,000, underscoring the company’s continued focus on research and development rather than commercial sales.
The company remains firmly in the clinical development phase, with no operating revenue and no dividends declared. Cash reserves stood at $6.22 million at year-end, supported by a $5 million placement in December 2025 and a $1.72 million R&D tax incentive refund.
Pivotal US Trial Milestone and Biomarker Expansion
FY2026 marked a turning point for Cleo as it completed blood sample collection for its pivotal US clinical trial, enrolling over 800 women across 19 sites. This trial is critical to demonstrating the efficacy of its Pre-Surgical Ovarian Cancer Test, which uses a patented CXCL10 biomarker alongside an expanded panel now comprising eight markers, up from five.
The enhanced biomarker panel aims to improve the test’s accuracy and scalability, vital for commercial deployment. Cleo has also partnered with Bio-Techne to manufacture the test on the Ella™ platform, a microfluidic system capable of multiplex biomarker measurement within a single sample.
Regulatory Progress and US Market Strategy
The company received positive feedback from a second pre-submission meeting with the US Food and Drug Administration (FDA) and has commenced the Analytical Validation phase ahead of a targeted FDA 510(k) submission in the first half of calendar 2027. Cleo also completed Stage One of the Medical Device Single Audit Program (MDSAP), facilitating smoother regulatory approval pathways in other jurisdictions such as Australia’s TGA.
Commercially, Cleo plans a capital-light US launch via a business-to-business laboratory model, leveraging existing pathology networks. It intends to use the existing miscellaneous CPT code 81599 for reimbursement immediately after FDA clearance, enabling case-by-case billing and real-world data collection. Pricing discussions are benchmarked against established multi-biomarker assays like OVA1, which are reimbursed between US$500 and US$900 per test.
Strategic Focus on Modular Market Entry
Cleo’s staged approach begins with the pre-surgical triage test, addressing a clear clinical need to differentiate benign from malignant ovarian masses before surgery. Success here is designed to validate the technology, build clinical evidence, and generate revenue to fund further development of recurrence monitoring and population screening tests. The latter represents the largest market opportunity but carries higher scientific and regulatory hurdles.
Risks and Funding Outlook
The company acknowledges significant risks typical of medical diagnostics development, including the inherent uncertainty of research outcomes, intellectual property protection, regulatory approval processes, and product liability. Cleo’s current budget covers the next two years, but further capital raising is anticipated to complete development and support commercialisation.
Directors and executives are remunerated primarily through fixed salaries and share-based payments, with no short-term incentives paid during FY2026. The company’s shares closed at $0.50, up from $0.39 a year earlier, despite the widening loss.
Looking Ahead
Key upcoming milestones include completing analytical validation batches, finalising the commercial assay algorithm, analysing pivotal trial data, and submitting the FDA 510(k) application in early 2027. Post-clearance, the focus will shift to US commercial launch, real-world evidence generation, and advancing recurrence and screening test programs.
Cleo’s progress toward regulatory approval and commercialisation will be critical to watch, particularly given the company’s reliance on successful FDA clearance and reimbursement negotiations to transition from a development-stage biotech to a revenue-generating diagnostics company. The path remains challenging, but the potential impact on ovarian cancer detection offers a compelling clinical and market opportunity.
Bottom Line?
Cleo’s transition from R&D to commercial stage hinges on FDA clearance and reimbursement success, with further capital needs ahead.
Questions in the middle?
- Will Cleo’s expanded biomarker panel deliver the accuracy needed for FDA approval and market adoption?
- How swiftly can Cleo secure broader reimbursement beyond the initial CPT code to scale US commercialisation?
- What funding strategies will the company pursue to bridge the gap from clinical validation to sustainable revenue?